Lilly oral cephalosporin product is showing "sales growth in the mid-teens" percentage range in 1990, Exec VP and Pharmaceutical Division President Eugene Step told Mabon Nugent research conference Dec. 5. Eleven-year old oral cephalosporin cefaclor loses patent exclusivity in mid-1992, but Step said generic competitors "may be in for a bit of a surprise" because cefaclor's "complex production process" may keep generic companies from seeking to market product. He noted that, outside the U.S. where no patent protection exists, Lilly knows of no generic Ceclor on the market or in development. Lilly's H antagonist Axid (nizatidine) and Humatrope (somatropin) human growth hormone are both growing in sales "well above 50% this year," Step said, with Humatrope expected to top $100 mil. in sales, the eighth Lilly drug to exceed that milestone. Carbacephem broad spectrum antibiotic loracarbef NDA is "on track at FDA," he noted.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.